Sales Up 6.7% but Operating Profit Down 19%, Net Profit Plunges 30% (Preliminary)


  • Revenue: 1,692,403 million KRW (+6.7% YoY)
  • Operating profit: 80,567 million KRW (-19.0% YoY)
  • Profit before income tax: 81,652 million KRW (-20.0% YoY)
  • Net profit: 77,826 million KRW (-30.2% YoY)
  • Total assets: 1,798,224 million; total liabilities: 791,868 million; total equity: 1,006,355 million
  • Reasons: increased SG&A and R&D expenses, base effect from prior-year one-off corporate tax refund
  • Unaudited, subject to change

KOSPI Filing Information


  • Filing: Change in Sales or Profit Structure of 30% (15% for Large Corporations) or More
  • Company: Chong Kun Dang Pharmaceutical (185750)
  • Submission: Chong Kun Dang Pharmaceutical Corp.
  • Receipt: 02-02-2026
  • Under KRX KOSPI Market Division